D. Foard

发表

Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light‐chain (AL) amyloidosis

A. Petrie, P. Hawkins, P. Bass, 2021, British journal of haematology.

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

A. Petrie, P. Hawkins, P. Bass, 2017, Kidney international.

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis

P. Hawkins, M. Fontana, C. Whelan, 2021, Leukemia.

Interim analysis of ALCHemy – a prospective study of 1000 patients with Systemic AL amyloidosis

P. Hawkins, M. Fontana, C. Whelan, 2015 .

Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis

A. Petrie, P. Hawkins, M. Fontana, 2022, Heart.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

P. Hawkins, M. Fontana, C. Whelan, 2018, Blood.

Six-minute walk test (6MWT) in AL amyloidosis – baseline and 12-month follow-up after chemotherapy

P. Hawkins, T. Lane, J. Gillmore, 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year

P. Hawkins, M. Fontana, C. Whelan, 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

M. Dimopoulos, A. Foli, P. Milani, 2013, Blood.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers

A. Petrie, P. Hawkins, M. Fontana, 2019, British journal of haematology.

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

P. Hawkins, C. Whelan, A. Wechalekar, 2014, Leukemia.

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

P. Hawkins, J. Pinney, C. Whelan, 2011, Blood.

Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens

P. Hawkins, J. Pinney, C. Whelan, 2014, British journal of haematology.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

P. Hawkins, M. Fontana, C. Whelan, 2019, Blood.

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting

P. Hawkins, J. Pinney, C. Whelan, 2014, Haematologica.

prolonged progression-free survival amyloidosis is associated with high clonal response rates and Cyclophosphamide, bortezomib, and dexamethasone therapy in AL

P. Hawkins, C. Whelan, H. Lachmann, 2012 .

A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort

P. Hawkins, M. Fontana, C. Whelan, 2014 .

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

M. Dimopoulos, P. Milani, M. Liedtke, 2021, Blood.

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

M. Dimopoulos, P. Milani, M. Liedtke, 2021, Blood.

Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.

R. Falk, A. Petrie, P. Hawkins, 2021, European heart journal.

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib

P. Hawkins, M. Fontana, C. Whelan, 2021, Blood Cancer Journal.

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

P. Milani, M. Liedtke, A. Dispenzieri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis

P. Hawkins, M. Fontana, C. Whelan, 2018, Haematologica.

Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

O. Berlanga, P. Hawkins, M. Fontana, 2022, Blood.

Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real‐world longitudinal data

P. Hawkins, M. Fontana, C. Whelan, 2021, British journal of haematology.

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis

P. Hawkins, M. Fontana, C. Whelan, 2021, Leukemia.

Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.

P. Hawkins, C. Whelan, A. Wechalekar, 2016, American journal of clinical pathology.

Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis

P. Hawkins, A. Wechalekar, T. Lane, 2015, Haematologica.

ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis

P. Hawkins, J. Pinney, S. Banypersad, 2011 .

Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort

P. Hawkins, M. Fontana, C. Whelan, 2022, American journal of hematology/oncology.

Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis

P. Hawkins, A. Wechalekar, H. Lachmann, 2023, British journal of haematology.

CHARACTERISTICS AND OUTCOMES OF 714 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS -ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY (ALCHEMY STUDY)

C. Whelan, A. Wechalekar, T. Lane, 2014 .